Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00177931

Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit

Evidence of Liver Transplantation Clinical Trial

Official title:
Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit

Clinical Trial Summary

The purposes of this study are to:

I. Characterize the plasma concentration-time profile of cefepime in liver transplant patients to determine the pharmacokinetic parameters in this patient population.

II. Perform stochastic modeling using the population pharmacokinetic parameters obtained in Specific Aim I to determine the ideal dose and dosing regimen of cefepime required to attain predetermined therapeutic targets in liver transplant patients.

Clinical Trial Description

The use of cefepime in liver transplant patients at conventional doses used for other patient populations leads to non-optimal drug exposure among liver transplant patients. Furthermore, using serum creatinine as a method of estimating creatinine clearance is not the optimal way to determine the best cefepime dose. The consequence of this non-optimal exposure is the unattainability of therapeutic targets. These therapeutic targets are correlated with positive microbiologic outcome and clinical cure. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

  • Evidence of Liver Transplantation
Clinical Trial Details
NCT number NCT00177931
Study type Observational
Source University of Pittsburgh
Contact
Status Completed
Phase N/A
Start date March 2005
Completion date December 2009
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02239991 - Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant N/A
Recruiting NCT03013634 - Protective Effects of Dexmedetomidine on Myocardial Injury During Liver Transplantation N/A
Active, not recruiting NCT02579408 - Quantifying Steatosis in Liver Transplant Donors
Completed NCT02008097 - Clinical Benefits of B-Flow Ultrasound N/A
Completed NCT04763096 - Evaluate the Efficacy and Safety of the ADVAGRAF® Phase 4
Recruiting NCT01607788 - Prospective Liver Tumor (ProLiT) Database N/A
Recruiting NCT01766518 - The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1) Phase 4
Not yet recruiting NCT01860716 - Impact of Melatonin in the Pretreatment of Organ Donor and the Influence in the Evolution of Liver Transplant. Phase 3
Completed NCT01022476 - Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients Phase 1/Phase 2
Completed NCT01546064 - Study to Establish Whether the Use of T-Tube in Bile Duct Anastomosis in Liver Transplantation Decreases Morbidity N/A
Completed NCT02263703 - Immunogenicity of HPV Vaccine in Immunosuppressed Children Phase 3
Terminated NCT00473824 - Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation Phase 2
Terminated NCT00151632 - Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil After Liver Transplantation Phase 3
Active, not recruiting NCT02350218 - Safety, Efficacy of Eglandin® in Living Donor Liver Transplanted Patient (PROVISION) Phase 2
Completed NCT02608606 - Determining Equivalence Dose for Oral Versus Sublingual Administration of Tacrolimus in Hepatic Receptors N/A
Recruiting NCT02451046 - Usefulness of Alpha-GST in Liver Transplantation N/A
Completed NCT01147380 - Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation Phase 1
Terminated NCT00694408 - A Pilot Trial of Pediatric Liver Transplantation Without Steroids Phase 3
Terminated NCT00375895 - Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation Phase 3
Recruiting NCT01157403 - Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients With Onset of Type 1 Diabetes Phase 2/Phase 3